Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice regarding 3,000 Performance Shares associated with the issuer, dated 01/14/2026. The filing lists multiple recent open-market sales by Solomon Moshkevich in 2026, with individual transactions and proceeds recorded between 02/02/2026 and 04/29/2026.
Natera Inc reports a Schedule 13G showing Vanguard Capital Management beneficially owns 7,205,939 shares of Common Stock, representing 5.08% of the class.
The filing states Vanguard Capital Management has sole dispositive power over 7,205,939 shares and sole voting power for 1,197,443 shares. Ownership is reported on behalf of Vanguard funds and managed accounts.
Natera, Inc.'s Chief Financial Officer, Michael Burkes Brophy, reported selling a total of 5,063 shares of Common Stock in open-market transactions on April 27 and April 29, 2026, at prices around the low-$200 to high-$190 range per share.
According to the footnotes, these sales were carried out to cover tax withholding and remittance obligations tied to the vesting of Restricted Stock Units granted in 2023 and 2024, and were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly holds 58,291 shares, indicating he retains a substantial equity stake.
Natera, Inc. CEO and President Steven Leonard Chapman reported selling a total of 5,838 shares of Natera common stock in open-market transactions on April 27, 2026. The footnotes state these sales were made to cover tax withholding and remittance obligations tied to the vesting of Restricted Stock Units and were executed under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions.
Natera, Inc. President and Chief Business Officer John Fesko sold a total of 1,688 shares of common stock on April 27, 2026 in two open-market transactions at prices of about $204 per share. According to the disclosure, these sales were executed to satisfy tax withholding and remittance obligations arising from the vesting of Restricted Stock Units and were carried out under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Natera, Inc. president Solomon Moshkevich reported routine share sales tied to tax withholding obligations. On April 27, 2026, he sold a total of 2,182 shares of Natera common stock in open-market transactions at prices around $204 per share.
The footnotes explain that both sales were executed solely to cover tax withholding and remittance arising from the vesting of Restricted Stock Units granted in January 2023 and January 2024. The transactions were carried out under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold a total of 1,861 shares of common stock in open‑market transactions. The sales, at prices of $204.39 and $203.75 per share, were made to satisfy tax withholding and remittance obligations arising from the vesting of Restricted Stock Units.
According to the filing, these transactions were executed under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, tied to stock unit agreements granted in January 2023 and January 2024. After these sales, Rabinowitz directly holds 223,024 shares of Natera common stock.
Natera, Inc. director and co‑founder Sheena Jonathan reported open‑market sales of 3,544 shares of Common Stock on April 27 and April 29, 2026, at prices around $196–$204 per share. After these trades, she directly holds 255,711 shares of Natera common stock.
Footnotes explain that certain sales were made to cover tax withholding and remittance obligations tied to the vesting of Restricted Stock Units and were effected pursuant to written instructions intended to satisfy Rule 10b5‑1(c) under the Exchange Act, including a trading plan adopted on December 11, 2024. Additional shares are held by the Caraluna 1 Trust and Caraluna 2 Trust, and Sheena Jonathan disclaims beneficial ownership of those trust securities.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice relating to proposed and recent resale of Common shares of NTRA. The notice lists 3,070 Restricted Stock Units proposed for sale on 04/26/2026. It also records prior 10b5-1 plan sales by Michael Burkes Brophy of 5,671 shares on 02/03/2026 and 785 shares on 03/10/2026.
Natera, Inc. director Herm Rosenman reported receiving equity-based compensation in the form of restricted stock units (RSUs). The filing shows two acquisitions of common stock via RSU awards on April 24, 2026, recorded at no cash cost per share to him.
One RSU grant was issued in lieu of quarterly board retainer fees of $23,750 and was fully vested at issuance, effectively converting a cash fee into share-based pay. A separate RSU award vests 25% immediately, with the remainder vesting in three equal quarterly installments, adding time-based incentives to his compensation.